6. Name of Product KOATE Licence Number: PL 0055/0065

7. Address for reply:

Mrs. M.W. Tatt,
Miles Laboratories Limited,
Stoke Court,
Stoke Poges,
Slough,
SL2 4LY,
Berkshire.

8. Give the present product particulars and proposed change. If the change refers to particulars on the Schedule of the product licence you should give them exactly as they currently appear on the licence and how you propose they should be stated (continue on a separate sheet if necessary). Please attach supporting evidence to the application and indicate the number of volumes and copies.

| *Present* | *Proposed* |
|---|---|
| SPECIFICATION OF SOURCE MATERIAL<br><br>Cutter System of Plasmapheresis incorporates all FDA requirements for Source Plasma. | SPECIFICATION OF SOURCE MATERIAL<br><br>Cutter System of Plasmapheresis incorporates all FDA requirements for Source Plasma. In addition, HB$_c$ Antibody test now included in the Cutter System. (Details attached, 2 copies). |

9. I hereby make application for the above licence to be changed in accordance with the proposals given above and certify that the changes will not adversely affect the quality of the product.

Signed GRO-C: M W Tatt Date 10th May 1984.

Status Registration Manager.

10. The licensing authority *consents to/acknowledges your request to change the product licence as outlined at 8 above.

Please retain this form with the formal documents relating to the product licence as evidence of *approval/notification of the change.

Signed GRO-C Date 8 June 1984

A person authorised to sign on behalf of the Secretary of State for Social Services

DEPARTMENT OF HEALTH AND SOCIAL SECURITY

*Delete as appropriate

# MEDICINES ACT 1968

PRODUCT LICENCE No. 0055 / 0065 has been granted under and subject to the provisions of the Medicines Act 1968 to

Miles Laboratories Ltd
T/A Cutter Laboratories (Division of Miles Laboratories Ltd)
Stoke Court
Stoke Poges
Slough
SL2 4LY

in respect of the products, particulars of which are set out in Part 1 of the attached Schedule. The Licence is subject to the further provisions set out or referred to in Part 2 of the said Schedule.

This Licence, unless previously suspended, revoked or varied as to the period of its validity, shall continue in force until the end of a period of five years from the date on which it was granted.

Date granted: 16 August 1983

GRO-C

A person authorised to sign on behalf of the Secretary of State for Social Services.

16 AUGUST 19 83

Department of Health and Social Security
Medicines Division
Market Towers
1 Nine Elms Lane
LONDON SW8 5NQ

IR/15

# MEDICINES ACT 1968

Product Licence No. 0055 / 0065

## SCHEDULE

### Part 1 - PARTICULARS OF THE PRODUCTS TO WHICH THE LICENCE RELATES

1. Name of Product: **Antihaemophilic Factor (Human) KOATE**

2. Pharmaceutical form: **Sterile lyophilized powder for reconstitution with sterile water for injection.**

3. Active constituents: **Factor VIII concentrate which becomes the therapeutic agent upon reconstitution** with the suitable volume of sterile water for injection.

4. Uses: Antihemophilic Factor (Human) is indicated in the treatment of classical hemophilia (hemophilia A) in which there is a demonstrated deficiency of Factor VIII activity.

5. Recommended dose and dosage schedule: The following formulae provide a guide for dosage calculations:

Expected Factor VIII increase (in % of normal) =

$$\frac{\text{IU administered} \times 2.0}{\text{bodyweight (in kg)}}$$

IU required = bodyweight (kg) x desired Factor VIII (% normal) x 0.5

All efforts should be made to follow the course of therapy with Factor VIII level assays. It may be dangerous to assume any certain level has been reached unless direct evidence is obtained.

6. Contra-indications Precautions and Warnings:

Contraindications

There are no specific contraindications to the use of Antihaemophilic Factor (Human).

Precautions

1. Antihaemophilic Factor (Human), Koate$^{R}$, is intended for treatment of bleeding disorders arising from a deficiency in Factor VIII. This deficiency should be proven prior to administering Koate, since no benefit may be expected from its use in treating other causes of haemorrhage.

2. After reconstitution, administer promptly (within 3 hours). Do not refrigerate after reconstitution. NOTE: The recommendation to administer promptly after reconstitution is intended to avoid the ill

MEDICINES ACT 1968

Product Licence No. 0055 / 0065

SCHEDULE

Part 1 - PARTICULARS OF THE PRODUCTS TO WHICH THE LICENCE RELATES

6. Contra-indications Precautions and Warnings:

effect of any possible bacterial contamination occurring during reconstitution. Koate is fully stable, without potency loss for at least 24 hours at room temperature after reconstitution

3. Administer only by the intravenous route.

4. A filter needle should be used prior to administering

5. Koate contains levels of blood group isoagglutinins which are not clinically significant when controlling relatively minor bleeding episodes. When large or frequently repeated doses are required in patients of blood groups A, B or AB, the possibility of intravascular haemolysis should be considered.

6. Administration equipment and any reconstituted Koate not used should be discarded.

Warning

Koate concentrate is a purified dried fraction of pooled plasma obtained from many paid donors. The presence of hepatitis viruses should be assumed and the hazard of administering Koate concentrate should be weighed against the medical consequence of witholding it, particularly in persons with few previous transfusions of blood or blood products.

7. Legal Category: PRESCRIPTION ONLY MEDICINE

8. Method of retail sale or supply: To haemophilia centres as a prescription item.

9. Manufacturer of dosage form: Cutter Laboratories Inc

A. Antihemophilic Factor (Human)
- Berkeley, California, USA
- Clayton, North Carolina, USA

B. Sterile Water for injection
- Chatanooga, Tennesee, USA

# MEDICINES ACT 1968

Product Licence No. 0055/ 0065

SCHEDULE

Part 2 - FURTHER PROVISIONS SUBJECT TO WHICH THE LICENCE HAS BEEN GRANTED

1. All the provisions of Part I of Schedule 1 of the Medicines (Standard Provisions for Licences and Certificates) Regulations 1971 (SI 1971 No 972) as amended by the Medicines (Standard Provisions for Licences and Certificates) Amendment Regulations 1972 (SI 1972 No 1226), the Medicines (Standard Provisions for Licences and Certificates) Amendment Regulations 1974 (SI 1974 No 1523), The Medicines (Standard Provisions for Licences and Certificates) Amendment Regulations 1977 (SI 1977 No 675) and the Medicines (Standard Provisions for Licences and Certificates) Amendment (No 2) Regulations 1977 (SI 1977 No 1039) shall apply.

2. Leaflets issued with proprietary medicinal products shall comply with the requirements of the Medicines (Leaflets) Regulations 1977 (SI 1977 No 1055). Labels of medicinal products shall comply with the Medicines (Labelling) Regulations 1976 (SI 1976 No 1726) as amended by the Medicines (Labelling) Amendment Regulations 1977 (SI 1977 No 996).

3. The product(s) shall not be recommended to be used for any purposes other than those specified in Part 1 of this Schedule as Uses.

4. The specification of the constituent and of the finished product shall be in accordance with the information contained in the application for this product licence.

5. The product shall be manufactured only in accordance with the method given in the application for this product licence.